Anticancer drug delivery with transferrin targeted polymeric chitosan vesicles

Christine Dufès, Jean-Marc Muller, William Couet, Jean-Christophe Olivier, I.F. Uchegbu, Andreas G. Schätzlein

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

The study reports the initial biological evaluation of targeted polymeric glycol chitosan vesicles as carrier systems for doxorubicin (Dox). Transferrin (Tf) was covalently bound to the Dox-loaded palmitoylated glycol chitosan (GCP) vesicles using dimethylsuberimidate (DMSI). For comparison, glucose targeted niosomes were prepared using N-palmitoyl glucosamine. Biological properties were studied using confocal microscopy, flow cytometry, and cytotoxicity assays as well as a mouse xenograft model. Tf vesicles were taken up rapidly with a plateau after 1-2 h and Dox reached the nucleus after 60-90 min. Uptake was not increased with the use of glucose ligands, but higher uptake and increased cytotoxicity were observed for Tf targeted as compared to GCP Dox alone. In the drug-resistant A2780AD cells and in A431 cells, the relative increase in activity was significantly higher for the Tf-GCP vesicles than would have been expected from the uptake studies. All vesicle formulations had a superior in vivo safety profile compared to the free drug. The in vitro advantage of targeted Tf vesicles did not translate into a therapeutic advantage in vivo. All vesicles reduced tumor size on day 2 but were overall less active than the free drug.
LanguageEnglish
Pages101-7
Number of pages94
JournalPharmaceutical Research
Volume21
Issue number1
DOIs
Publication statusPublished - 2004

Fingerprint

Chitosan
Transferrin
Drug delivery
Doxorubicin
Pharmaceutical Preparations
Cytotoxicity
Dimethyl Suberimidate
Glucose
Flow cytometry
Confocal microscopy
Glucosamine
Heterografts
Confocal Microscopy
Liposomes
Tumors
Assays
Flow Cytometry
Ligands
Safety
Neoplasms

Keywords

  • doxorubicin
  • glucose niosomes
  • glycol chitosan
  • polymeric vesicles
  • transferrin

Cite this

Dufès, Christine ; Muller, Jean-Marc ; Couet, William ; Olivier, Jean-Christophe ; Uchegbu, I.F. ; Schätzlein, Andreas G. / Anticancer drug delivery with transferrin targeted polymeric chitosan vesicles. In: Pharmaceutical Research. 2004 ; Vol. 21, No. 1. pp. 101-7.
@article{41643fbfd74045a9bf19c31bda30d8b1,
title = "Anticancer drug delivery with transferrin targeted polymeric chitosan vesicles",
abstract = "The study reports the initial biological evaluation of targeted polymeric glycol chitosan vesicles as carrier systems for doxorubicin (Dox). Transferrin (Tf) was covalently bound to the Dox-loaded palmitoylated glycol chitosan (GCP) vesicles using dimethylsuberimidate (DMSI). For comparison, glucose targeted niosomes were prepared using N-palmitoyl glucosamine. Biological properties were studied using confocal microscopy, flow cytometry, and cytotoxicity assays as well as a mouse xenograft model. Tf vesicles were taken up rapidly with a plateau after 1-2 h and Dox reached the nucleus after 60-90 min. Uptake was not increased with the use of glucose ligands, but higher uptake and increased cytotoxicity were observed for Tf targeted as compared to GCP Dox alone. In the drug-resistant A2780AD cells and in A431 cells, the relative increase in activity was significantly higher for the Tf-GCP vesicles than would have been expected from the uptake studies. All vesicle formulations had a superior in vivo safety profile compared to the free drug. The in vitro advantage of targeted Tf vesicles did not translate into a therapeutic advantage in vivo. All vesicles reduced tumor size on day 2 but were overall less active than the free drug.",
keywords = "doxorubicin, glucose niosomes, glycol chitosan, polymeric vesicles, transferrin",
author = "Christine Duf{\`e}s and Jean-Marc Muller and William Couet and Jean-Christophe Olivier and I.F. Uchegbu and Sch{\"a}tzlein, {Andreas G.}",
year = "2004",
doi = "10.1023/B:PHAM.0000012156.65125.01",
language = "English",
volume = "21",
pages = "101--7",
journal = "Pharmaceutical Research",
issn = "0724-8741",
number = "1",

}

Dufès, C, Muller, J-M, Couet, W, Olivier, J-C, Uchegbu, IF & Schätzlein, AG 2004, 'Anticancer drug delivery with transferrin targeted polymeric chitosan vesicles' Pharmaceutical Research, vol. 21, no. 1, pp. 101-7. https://doi.org/10.1023/B:PHAM.0000012156.65125.01

Anticancer drug delivery with transferrin targeted polymeric chitosan vesicles. / Dufès, Christine; Muller, Jean-Marc; Couet, William; Olivier, Jean-Christophe; Uchegbu, I.F.; Schätzlein, Andreas G.

In: Pharmaceutical Research, Vol. 21, No. 1, 2004, p. 101-7.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Anticancer drug delivery with transferrin targeted polymeric chitosan vesicles

AU - Dufès, Christine

AU - Muller, Jean-Marc

AU - Couet, William

AU - Olivier, Jean-Christophe

AU - Uchegbu, I.F.

AU - Schätzlein, Andreas G.

PY - 2004

Y1 - 2004

N2 - The study reports the initial biological evaluation of targeted polymeric glycol chitosan vesicles as carrier systems for doxorubicin (Dox). Transferrin (Tf) was covalently bound to the Dox-loaded palmitoylated glycol chitosan (GCP) vesicles using dimethylsuberimidate (DMSI). For comparison, glucose targeted niosomes were prepared using N-palmitoyl glucosamine. Biological properties were studied using confocal microscopy, flow cytometry, and cytotoxicity assays as well as a mouse xenograft model. Tf vesicles were taken up rapidly with a plateau after 1-2 h and Dox reached the nucleus after 60-90 min. Uptake was not increased with the use of glucose ligands, but higher uptake and increased cytotoxicity were observed for Tf targeted as compared to GCP Dox alone. In the drug-resistant A2780AD cells and in A431 cells, the relative increase in activity was significantly higher for the Tf-GCP vesicles than would have been expected from the uptake studies. All vesicle formulations had a superior in vivo safety profile compared to the free drug. The in vitro advantage of targeted Tf vesicles did not translate into a therapeutic advantage in vivo. All vesicles reduced tumor size on day 2 but were overall less active than the free drug.

AB - The study reports the initial biological evaluation of targeted polymeric glycol chitosan vesicles as carrier systems for doxorubicin (Dox). Transferrin (Tf) was covalently bound to the Dox-loaded palmitoylated glycol chitosan (GCP) vesicles using dimethylsuberimidate (DMSI). For comparison, glucose targeted niosomes were prepared using N-palmitoyl glucosamine. Biological properties were studied using confocal microscopy, flow cytometry, and cytotoxicity assays as well as a mouse xenograft model. Tf vesicles were taken up rapidly with a plateau after 1-2 h and Dox reached the nucleus after 60-90 min. Uptake was not increased with the use of glucose ligands, but higher uptake and increased cytotoxicity were observed for Tf targeted as compared to GCP Dox alone. In the drug-resistant A2780AD cells and in A431 cells, the relative increase in activity was significantly higher for the Tf-GCP vesicles than would have been expected from the uptake studies. All vesicle formulations had a superior in vivo safety profile compared to the free drug. The in vitro advantage of targeted Tf vesicles did not translate into a therapeutic advantage in vivo. All vesicles reduced tumor size on day 2 but were overall less active than the free drug.

KW - doxorubicin

KW - glucose niosomes

KW - glycol chitosan

KW - polymeric vesicles

KW - transferrin

U2 - 10.1023/B:PHAM.0000012156.65125.01

DO - 10.1023/B:PHAM.0000012156.65125.01

M3 - Article

VL - 21

SP - 101

EP - 107

JO - Pharmaceutical Research

T2 - Pharmaceutical Research

JF - Pharmaceutical Research

SN - 0724-8741

IS - 1

ER -